3rd Quarter - Report

MEHLMAN CONSULTING, INC. for ASTRAZENECA PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Budget issues, including Medicare Part D Rebates. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package. Health reform implementation. Independent Payment Advisory Board. Budget Control Act of 2011 (Became PL 112-25 on August 2, 2011)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

International trade issues, including free-trade agreements; import safety.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax issues, including repatriation, deferral and carried interest.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Health care reform: implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness. H.R. 2182, Generating Antibiotic Incentives Now (GAIN) Act. Prescription Drug User Fee Act (PDUFA)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2182 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.